CD33 and acute myeloid leukemia: When TV6 was combined with the TKI, quizartinib (AC220), in a FLT3-ITD patient-derived xenogfaft (PDX) model, primary AML cell engraftment (CD45+/CD33+/FLT3-ITD) was significantly reduced in comparison to quizartinib alone.